An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.

被引：1
|
作者：
Decoster, Lore
Cappoen, Nadia
Aftimos, Philippe Georges
Raicevic, Gordana
Rolfo, Christian Diego
Rottey, Sylvie
Duhoux, Francois P.
Collignon, Joelle
Hebrant, Aline
Vandenbulcke, Marc
De Greve, Jacques
机构：
[1] UZ Brussel, Brussels, Belgium
[2] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
[3] Belgian Soc Med Oncol, Brussels, Belgium
[4] Univ Antwerp Hosp, Edegem, Belgium
[5] Ghent Univ Hosp, Heymans Inst Pharmacol, Ghent, Belgium
[6] Clin Univ St Luc, King Albert II Canc Inst, Dept Med Oncol, Brussels, Belgium
[7] Catholic Univ Louvain, Inst Rech Expt & Clin Pole MIRO, Brussels, Belgium
[8] CHU Sart Tilman, Liege, Belgium
[9] Wetenschappelijk Inst Volksgezondheid Belgie, Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS2615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2615
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
    Decoster, L.
    Aftimos, P. G.
    Rottey, S.
    Prenen, H.
    Collignon, J. J.
    Mebis, J.
    Canon, J-L.
    Fastenaekels, V.
    Cappoen, N.
    Joris, S. R.
    De Greve, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S262 - S262
  • [2] Effects of HER2 and HER3 on EGFR trafficking and localization - a modelling study
    Resat, H
    Shankaran, H
    Wiley, H
    MOLECULAR BIOLOGY OF THE CELL, 2004, 15 : 13A - 13A
  • [3] Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers
    Desai, Monica Dandona
    Saroya, Bikramajit Singh
    Lockhart, Albert Craig
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (03) : 341 - 356
  • [4] Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation.
    Piha-Paul, Sarina Anne
    Fu, Siqing
    Hong, David S.
    Janku, Filip
    Karp, Daniel D.
    Naing, Aung
    Pant, Shubham
    Ahnert, Jordi Rodon
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Yap, Timothy Anthony
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
    Sarina A. Piha-Paul
    Chieh Tseng
    Hai T. Tran
    Meng Gao
    Daniel D. Karp
    Vivek Subbiah
    Apostolia Maria Tsimberidou
    Jitesh D. Kawedia
    Siqing Fu
    Shubham Pant
    Timothy A. Yap
    Van K. Morris
    Bryan K. Kee
    Mariela Blum Murphy
    JoAnn Lim
    Funda Meric-Bernstam
    Cancer Chemotherapy and Pharmacology, 2023, 92 : 107 - 118
  • [6] A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
    Piha-Paul, Sarina A.
    Tseng, Chieh
    Tran, Hai T.
    Gao, Meng
    Karp, Daniel D.
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Kawedia, Jitesh D.
    Fu, Siqing
    Pant, Shubham
    Yap, Timothy A.
    Morris, Van K.
    Kee, Bryan K.
    Blum Murphy, Mariela
    Lim, JoAnn
    Meric-Bernstam, Funda
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (02) : 107 - 118
  • [7] Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine
    Disis, M. L.
    Salazar, L. G.
    Coveler, A.
    Waisman, J.
    Higgins, D.
    Childs, J.
    Bates, N.
    Dang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Sarina A. Piha-Paul
    Analía Azaro
    Hendrik Tobias Arkenau
    Do-Youn Oh
    Matthew D. Galsky
    Sumanta Kumar Pal
    Kensuke Hamada
    Yaohua He
    Ikuo Yamamiya
    Karim A Benhadji
    Antoine Hollebecque
    Investigational New Drugs, 2021, 39 : 1324 - 1334
  • [9] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Piha-Paul, Sarina A.
    Azaro, Analia
    Arkenau, Hendrik Tobias
    Oh, Do-Youn
    Galsky, Matthew D.
    Pal, Sumanta Kumar
    Hamada, Kensuke
    He, Yaohua
    Yamamiya, Ikuo
    Benhadji, Karim A.
    Hollebecque, Antoine
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1324 - 1334
  • [10] Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer
    Kurata, Takayasu
    Tsurutani, Junji
    Fujisaka, Yasuhito
    Okamoto, Wataru
    Hayashi, Hidetoshi
    Kawakami, Hisato
    Shin, Eisei
    Hayashi, Nobuya
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (05) : 946 - 954
12345